Runnymede Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Runnymede Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277K	Hold	1,748	–	–	0.16%	62
2026 Q1	$223K	Buy	+1,748	New	+$218K	0.19%	67
2025 Q2	–	Sell	-1,782	Closed	-$145K	–	274
2025 Q1	$145K	Hold	1,782	–	–	0.14%	83
2024 Q4	$160K	Buy	+1,782	New	+$173K	0.14%	82

Other funds holding XBI

LMFP

Larry Mathis Financial Planning Phoenix, Arizona $124B AUM

PSP Research Newtown Square, Pennsylvania $188M AUM

AAS

Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return

WAM

Weatherly Asset Management Del Mar, California $1.4B AUM 36.32% 1-Year Est. Return

RFM

Royal Fund Management Lady Lake, Florida $1.2B AUM 32.21% 1-Year Est. Return

MFS

Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $132M AUM 24.1% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

LHWM

Lake Hills Wealth Management Austin, Texas $220M AUM 39.11% 1-Year Est. Return

MWA

MFA Wealth Advisors Pittsburgh, Pennsylvania $587M AUM 27.44% 1-Year Est. Return

Runnymede Capital Advisors's XBI Position: Q2 2026 in Review

Runnymede Capital Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q2 2026 at 1,748 shares worth $277K. The position accounts for 0.16% of the portfolio, ranked #62.

Runnymede Capital Advisors first reported a position in XBI in Q4 2024 and has held it in 4 quarters since. 201 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Runnymede Capital Advisors held 1,748 shares of State Street SPDR S&P Biotech ETF worth $277K as of Q2 2026.
Runnymede Capital Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.16% of Runnymede Capital Advisors's portfolio in Q2 2026, its #62 holding.
Runnymede Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q4 2024 and has held it in 4 quarters since.
201 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Runnymede Capital Advisors's 13F filing for Q2 2026, filed 21 Jul 2026.